MP36-07 UNDERSTANDING THE EFFECTS OF ACTINIDIN AS A COLLAGENASE ACTING TO TREAT HUMAN PEYRONIE’S DISEASE CELLS
Notice bibliographique
Résumé
You have accessJournal of UrologyCME1 Apr 2023MP36-07 UNDERSTANDING THE EFFECTS OF ACTINIDIN AS A COLLAGENASE ACTING TO TREAT HUMAN PEYRONIE’S DISEASE CELLS Kevin Feng, Wongsakorn Kiattiburut, Duane Hickling, Jeremy Burton, and Jeffrey Campbell Kevin FengKevin Feng More articles by this author , Wongsakorn KiattiburutWongsakorn Kiattiburut More articles by this author , Duane HicklingDuane Hickling More articles by this author , Jeremy BurtonJeremy Burton More articles by this author , and Jeffrey CampbellJeffrey Campbell More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003270.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Peyronie’s Disease (PD) is a penile connective tissue disorder that affects approximately 10% of men. The collagenous plaques that hallmark the disease can result in penile curvature, painful erections, and/or erectile dysfunction. Intralesional injection of collagenase Clostridium histolyticum is the only FDA approved treatment for PD, however, is no longer available in Canada. The enzyme actinidin has the ability to hydrolyze collagen and fibrinogen. Our preliminary work has evaluated actindin on in vitro cellular PD models. Our objectives are to determine the mechanism by which actinidin can reduce collagen composition of in vitro human PD models and explore the cytotoxicity and gene expression of cells treated with actinidin. METHODS: Three human PD tissue groups were isolated for fibroblast cells and cultured using complete media. The cells were plated on a 96-well plate and treated with their respective treatments: media, saline, verapamil, actinidin at 50, 25 and 10 mg/ml for 24 hours. MTT assay, immunofluorescent staining, qPCR and collagen quantification assay were used to examine cellular cytotoxicity, cellular organization/morphology, and gene expression, respectively. Statistical analyses were employed using Python 3 and Prism 10. RESULTS: Actinidin significantly reduced the amount of cellular-bound collagen (p<0.01) in our human PD model. The immunofluorescent staining of smooth muscle actin showed a significant increase of normalized actin stained signal, suggesting possible compromise of the cell membrane of PD cells. Microscopic observation of cellular morphology demonstrated the increases of interstitial space in the actinidin treated group compared to negative control, indicating the alteration of extra cellular matrix. MTT assay demonstrated that high concentration of actinidin reduced cellular viability of the PD cells. CONCLUSIONS: Our preliminary study suggests the possible effects of actinidin in breaking down PD plaques by compromising the extracellular matrix, membrane-bound proteins, and the cellular membrane of human PD fibroblasts. An increased level of normalized actin in the high concentration actinidin group acts suggests a compromised plasma membrane and a potential mechanism of action. Further studies will investigate the optimal actinidin concentration that can safely reduce the collagen composition of human PD plaques. In the absence of durable FDA-approved treatments for PD in Canada, this novel option could offer future treatment potential. Source of Funding: Canadian Urology Association Scholarship Foundation - Canadian Mens Sexual Health Council © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e481 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kevin Feng More articles by this author Wongsakorn Kiattiburut More articles by this author Duane Hickling More articles by this author Jeremy Burton More articles by this author Jeffrey Campbell More articles by this author Expand All Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».